It is far from a controversial statement that biologic therapeutics – such as monoclonal antibody and recombinant protein therapies – are complex and expensive to develop. As one might... read more →
Statistics is hard, words are harder. So often when working through the statistics behind a bioassay, the correct path is obscured behind a word salad of jargon placed seemingly... read more →
So far in our series examining approaches to outlier management in bioassay, we’ve discussed the various perspectives on outliers held by stakeholders in the bioassay lifecycle and the problems... read more →
Previously, we examined the reasons why one might consider attempting to identify and remove outliers from bioassay data. From a scientific perspective, omitting any collected data is never ideal,... read more →
Outliers are among the topics which stimulate the most vigorous debate among the bioassay community. When a datapoint falls outside of the usual range observed for that metric, it... read more →